Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Gail J. Roboz(Presbyterian Hospital), Katherine Walsh(The Ohio State University), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Ellen K. Ritchie(Presbyterian Hospital), Patricia Kropf(Fox Chase Cancer Center), Casey L. O’Connell(University of Southern California), Raoul Tibes(Mayo Clinic in Arizona), Scott D. Lunin(Clinical Physiology Associates), Todd Rosenblat(Columbia University Irving Medical Center), Karen Yee(Princess Margaret Cancer Centre), Wendy Stock(University of Chicago), Elizabeth A. Griffiths(Roswell Park Comprehensive Cancer Center), Joseph R. Mace(Florida Cancer Specialists & Research Institute), Nikolai A. Podoltsev(Yale University), Jesús G. Berdeja(Sarah Cannon), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Jean‐Pierre J. Issa(Temple University), Yong Hao(Astex Pharmaceuticals), Harold Keer(Astex Pharmaceuticals), Mohammad Azab(Astex Pharmaceuticals), Michael R. Savona(Vanderbilt University)
Cited by 93Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis